Cyclophosphamide
Cyclophosphamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Colorectal Cancer、Metastatic Pancreatic Cancer、Metastatic Ovarian Cancer、Metastatic Breast Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
1 项
已进入 III/IV 期
8 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- Hackensack Meridian Health
- Northside Hospital, Inc.
- The University of Texas Health Science Center at San Antonio
- M.D. Anderson Cancer Center
- Masonic Cancer Center, University of Minnesota
- Weijia Fang, MD
- Chinese PLA General Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、西班牙、澳大利亚、加拿大、新西兰、Puerto Rico、South Korea
正在招募患者的 Cyclophosphamide 研究
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
II 期招募中美国NCT02605421Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
I 期招募中中国NCT06821048CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
I 期 / II 期招募中中国NCT05948033Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
II 期招募中中国NCT06088030Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
不适用招募中西班牙NCT07624838Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
不适用招募中中国NCT06529250A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
I 期招募中美国NCT03219450PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
II 期招募中美国NCT06245889NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
I 期招募中中国NCT05881525Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
I 期招募中美国NCT04301076DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
II 期招募中中国NCT05334823Pucotenlimab and Anlotinib in Combination With Chemotherapy
II 期招募中中国NCT07896668Treatment of Moderate to Severe Refractory Crohn's Disease
I 期 / II 期招募中美国NCT06721962Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
II 期招募中美国NCT04991103RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
II 期招募中中国NCT06674096Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
I 期招募中中国NCT07093073T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
II 期招募中美国NCT02133196CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
I 期招募中South KoreaNCT07855302A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
I 期招募中中国NCT07250386Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
II 期招募中中国NCT07635342I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
早期 I 期招募中中国NCT06469190
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。